Using Gadoxetate MRI to improve detection of liver metastases in colorectal cancer
Official title: A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT05314400 · Data updated 2026-11-12
This study is testing if a special type of MRI can better identify liver tumors in patients with colorectal cancer to help guide their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | October 1, 2026 |
| Study ends | October 1, 2027 |
| Registry record updated | July 11, 2025 |
| Trial ID | NCT05314400 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a biopsy-proven diagnosis of colorectal cancer and prior imaging indicating liver lesions.
✕Probably not a fit
Patients with diffuse liver metastases that are definitively unresectable or those with severe liver dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of Gadoxetate-enhanced MRI in detecting liver metastases in patients diagnosed with colorectal cancer. Patients who have previously undergone imaging that shows liver lesions will receive either a full or abbreviated Gadoxetate-enhanced MRI to assess the nature of these lesions. The study aims to determine if this imaging technique can provide better characterization of liver tumors, which is crucial for surgical planning and treatment decisions. Conducted at London Health Sciences Centre, the trial focuses on improving the accuracy of liver metastasis detection to enhance patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and characterization of liver metastases, improving surgical outcomes for colorectal cancer patients.
How similar studies have gone: Other studies have shown promising results with similar imaging approaches, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, 18 years of age or older * Diagnosis of colorectal cancer, biopsy proven * Prior imaging showing liver lesions that may be metastases * Provision of signed and dated informed consent form * Willingness to comply with study procedures and availability for the duration of the study * Able to tolerate MRI required by protocol Exclusion Criteria: * Presence of implanted medical device or metallic object that is MR incompatible * Baseline eGFR of \< 30 mL/min/1.73 m2 * Severe claustrophobia not relieved by oral anxiolytics * Documented severe allergic-like reaction gadolinium-based contrast agent * Weight greater than allowable on MRI table * Pregnancy * Diffuse liver metastases, i.e. definitively unresectable * Severe liver dysfunction, ALBI grade 3
Where it's running
-
St. Joseph's Healthcare
London, Ontario, Canada Recruiting -
London Health Sciences Centre
London, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Harry Marshall, MD/PhD
- Email: harry.marshall@lhsc.on.ca
- Phone: 519-685-8500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can hepatic artery infusion chemotherapy enable liver surgery for colorectal cancer that has spread to the liver?
This study tests whether hepatic artery infusion chemotherapy plus standard chemotherapy can make some inoperable colorectal liver metastases operable in patients.
-
Electrochemotherapy for unresectable visceral tumors including liver metastases
This will try electrochemotherapy with bleomycin in adults who have unresectable primary or metastatic visceral tumors, such as liver metastases.
-
Evaluating a new immuno-adjuvant for colorectal liver metastases after ablation treatments
This study is testing a new treatment called IP-001 to see if it can boost the immune response and help people with colorectal liver metastases feel better after they have undergone ablation therapies.
-
Comparing simultaneous and staged surgery for colorectal cancer with liver metastases
This study is testing whether doing surgery for colon cancer and liver tumors at the same time or in separate stages is better for patients in terms of recovery and overall health.
-
Comparing two treatments for colorectal liver metastases
This study is testing whether a new treatment called irreversible electroporation works better than stereotactic body radiotherapy for people with hard-to-treat colorectal cancer that has spread to the liver.
-
Using AI to improve treatment for liver tumors
This study is testing whether using artificial intelligence can help doctors choose the best treatments and predict outcomes for patients with liver tumors undergoing thermal ablation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.